Hims & Hers shares of health rose sharply on Wednesday, marking their strongest session in nearly three months, after the company launched a new menopause and perimenopause service under its Hers brand. The stock climbed 16.2% to close at $62.76, before slipping 2.2% in after-hours trading.

Bank of America’s research arm highlighted the service as a potential driver of growth for the company, noting that it expands Hims & Hers’ reach into a multi-billion-dollar women’s healthcare market. The brokerage said the move supports revenue diversification at a time when the men’s segment faces headwinds.

Personalized care service launched

The service provides women with access to tailored treatment plans for menopause and perimenopause symptoms such as hot flashes, mood changes, and sleep disturbances. Plans may include prescription hormone therapies, including estradiol and progesterone, delivered in pill, patch, or cream form. Licensed providers trained in menopause and perimenopause care oversee all treatments.

Jessica Shepherd, chief medical officer of Hers, said, “Women have been navigating an outdated healthcare system that wasn’t designed for them for too long. Hers was built to serve every woman on her terms.”

The company officially launched the service on Wednesday via its digital platform. Hers currently serves more than 500,000 subscribers and aims to surpass $1 billion in annual revenue by 2026. Bank of America said the new service could make a modest financial contribution in the fourth quarter of this year, with more substantial growth expected in 2026. Despite the positive outlook, the brokerage maintained an ‘Underperform’ rating on the stock with a $28 price target.

Investor sentiment rises Hims & Hers shares

Retail investor sentiment showed strong optimism on social media platforms. On Stocktwits, discussion volume about Hims & Hers shares surged 934% in 24 hours, with many users expressing bullish views. One user described the stock as the “best swing trade stock of 2025,” citing consistent gains from its volatility and predicting a potential move toward $100. Another noted that the recent breakout occurred on heavy volume and suggested a move toward $70 may be likely.

The stock’s strong session on Wednesday reflects investor interest in the company’s expansion into women’s healthcare and its potential to diversify revenue streams. Analysts note tha tHims & Hers shares s increasingly positioning itself as a digital-first provider of health services for women, a segment historically underserved by conventional healthcare systems.

Background on Hims & Hers shares

Hims & Hers Health, founded in 2017, is a telehealth company offering a range of prescription and over-the-counter health products. Its Hers brand focuses on women’s health, providing services that cover reproductive health, mental health, skin care, and now menopause and perimenopause care.

The company has grown rapidly in recent years, leveraging digital platforms to reach new customers and deliver personalized healthcare experiences. Expansion into hormone therapy and menopause care is seen as a strategic step to tap into the growing demand for women-centered health solutions.

As the healthcare industry continues to evolve, Hims & Hers’ approach reflects broader trends toward digital-first, personalized care, and the company aims to capture a larger share of the women’s health market. Investors and analysts will be monitoring adoption rates, subscription growth, and the financial contribution of the new service in the coming quarters

Also Read :– Hims & Hers Health Faces FDA Scrutiny Over Super Bowl Ad Risks